ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $2.08 billion. The enterprise value is $2.44 billion.
Important Dates
The last earnings date was Monday, March 3, 2025, before market open.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 730.16 million shares outstanding. The number of shares has increased by 37.71% in one year.
| Current Share Class | 730.16M |
| Shares Outstanding | 730.16M |
| Shares Change (YoY) | +37.71% |
| Shares Change (QoQ) | +5.24% |
| Owned by Insiders (%) | 40.49% |
| Owned by Institutions (%) | 12.15% |
| Float | 81.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 134.78 |
| Forward PS | 15.43 |
| PB Ratio | -4.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 165.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36
| Current Ratio | 3.36 |
| Quick Ratio | 2.77 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -48.48% |
| Return on Invested Capital (ROIC) | -137.11% |
| Return on Capital Employed (ROCE) | -104.94% |
| Revenue Per Employee | $23,479 |
| Profits Per Employee | -$658,541 |
| Employee Count | 628 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.49% in the last 52 weeks. The beta is -0.18, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.18 |
| 52-Week Price Change | -39.49% |
| 50-Day Moving Average | 3.01 |
| 200-Day Moving Average | 4.50 |
| Relative Strength Index (RSI) | 43.14 |
| Average Volume (20 Days) | 5,972,497 |
Short Selling Information
The latest short interest is 56.96 million, so 7.80% of the outstanding shares have been sold short.
| Short Interest | 56.96M |
| Short Previous Month | 55.92M |
| Short % of Shares Out | 7.80% |
| Short % of Float | 69.83% |
| Short Ratio (days to cover) | 9.09 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $14.75 million and -$413.56 million in losses. Loss per share was -$0.62.
| Revenue | 14.75M |
| Gross Profit | 14.75M |
| Operating Income | -344.18M |
| Pretax Income | -601.00M |
| Net Income | -413.56M |
| EBITDA | -326.63M |
| EBIT | -344.18M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $149.81 million in cash and $504.17 million in debt, giving a net cash position of -$354.36 million or -$0.49 per share.
| Cash & Cash Equivalents | 149.81M |
| Total Debt | 504.17M |
| Net Cash | -354.36M |
| Net Cash Per Share | -$0.49 |
| Equity (Book Value) | -488.13M |
| Book Value Per Share | -0.57 |
| Working Capital | 129.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$391.24 million and capital expenditures -$6.89 million, giving a free cash flow of -$398.12 million.
| Operating Cash Flow | -391.24M |
| Capital Expenditures | -6.89M |
| Free Cash Flow | -398.12M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,334.23% |
| Pretax Margin | -2,805.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |